{"entity":{"id":"adcc-adcp-cdc","kind":"term","name":"Antibody-guided effector mechanisms (ADCC, ADCP, CDC)","aka":["ADCP","CDC","antibody-dependent cellular phagocytosis","antibody-dependent cell-mediated cytotoxicity","complement-dependent cytotoxicity","opsonisation"],"tldr":"An antibody that coats a cell can lead to its removal in three different ways: immune cells that kill it, cells that swallow it, or blood proteins that damage its membrane. Seeing the coat does not show which of these happened.","summary":"Opsonisation means coating a target with molecules that help immune clearance. The antibody's Fc region can then connect that coat to effector cells or to complement, and three mechanisms name different downstream jobs. In antibody-dependent cellular cytotoxicity (ADCC) an effector cell, with the natural killer cell as the familiar example, triggers damage or death in a coated target, typically through an Fc gamma receptor such as CD16 engaging target-bound IgG. In antibody-dependent cellular phagocytosis (ADCP) a phagocyte such as a macrophage engulfs the coated target. In complement-dependent cytotoxicity (CDC) the complement protein C1q recognises a suitable arrangement of Fc regions and the cascade can end in membrane attack complexes. ADCC is not an exclusive cell-identity label: other immune populations can contribute antibody-dependent cytotoxicity.\n\nThe three routes can overlap and no universal ranking exists. Isotype and Fc design, target density, inhibitory signals and the availability of effectors or complement shape the result. Evidence differs in kind. Clynes et al. (2000) used mouse tumour models, including xenografts treated with the humanised antibodies trastuzumab and rituximab, and found that engagement of Fc gamma receptors on effector cells was a dominant component of in vivo antibody activity, with the inhibitory receptor FcgammaRIIB regulating it. Gül et al. (2014) imaged mice directly: liver macrophages (Kupffer cells) sampled circulating tumour cells without eliminating them, whereas antitumour antibody treatment produced rapid phagocytosis that depended on the Fc receptors FcgammaRI and FcgammaRIV. Diebolder et al. (2014) showed in cell and biochemical systems that ordered IgG hexamers assembled on the target surface recruit and activate C1, and that this could be manipulated to block or enhance complement killing across all four human IgG subclasses. None of these is a human treatment-benefit result.\n\nWhat each step shows is separate. Fc-receptor binding is not completed ADCC or ADCP. A phagocyte touching a target, or sampling a fragment, is not internalisation of a whole viable cell. Complement deposition (coating) is an earlier step than a membrane pore, and a pore is a different observation from measured lysis. Assays therefore name their output: target death for ADCC, the fraction of phagocytes with verified internalised targets for ADCP, membrane damage with active complement for CDC (heat-inactivated or depleted complement tests complement dependence). They use viable targets, defined antibody concentrations, no-antibody and target-negative controls, and report exposure time and effector-to-target ratio. Binding or reporter activation alone is an earlier readout, and stronger activity in a dish does not establish clinical benefit or healthy-tissue safety.","asOf":"2026-11-09","links":[{"label":"Clynes et al., 2000, Nature Medicine (PMID 10742152)","url":"https://doi.org/10.1038/74704"},{"label":"Gül et al., 2014, Journal of Clinical Investigation (PMID 24430180)","url":"https://doi.org/10.1172/JCI66776"},{"label":"Diebolder et al., 2014, Science (PMID 24626930)","url":"https://doi.org/10.1126/science.1248943"},{"label":"Serna et al., 2016: Structural basis of complement membrane attack complex formation","url":"https://doi.org/10.1038/ncomms10587"},{"label":"UniProt FCGR3A (CD16A): function and membrane topology","url":"https://www.uniprot.org/uniprotkb/P08637/entry"}],"tags":["education-immunology-2026-11"],"related":["adcc","fc-effector","complement-in-cancer","antibody","macrophage","nk-cell","fcgr3a","fcgr2b"],"cancers":[],"sections":[],"technologies":[],"targets":["fcgr3a","fcgr2a","fcgr2b"],"drugs":[],"companies":[],"institutions":[],"pathways":["complement-in-cancer"],"terms":["adcc","fc-effector","antibody","nk-cell","macrophage"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Evidence tiers: Clynes 2000 and Gül 2014 are mouse studies; Diebolder 2014 is a cell and biochemical study. Read from the Europe PMC abstracts on 9 November 2026; a textbook chapter on the same mechanisms (Janeway, Immunobiology) refused scripted access and was not opened, so nothing here rests on it.","In the NK-cell route, the Fc receptor sits on the NK-cell membrane and meets Fc exposed on the antibody-coated target. Fab tips recognise the target antigen. Granules are released into the space between the cells while the NK cell remains outside; this is different from engulfment. The NK-cell example does not make ADCC an exclusive name for one cell type.","For whole-cell ADCP, distinguish the phagocyte's boundary and nucleus from the target. A completed whole-target uptake schematic places the coated target, including its nucleus, inside a separate closed phagosome; the phagocyte's own nucleus stays outside that compartment. Contact or a fluorescent fragment does not demonstrate whole-cell internalisation. Gül and colleagues' mouse live-cell imaging separated fragment sampling, whole-cell phagocytosis and later degradation; these are different observations.","A completed membrane-attack pore crosses the two leaflets of one lipid bilayer, connecting the outside of a target cell with its interior. It is different from complement deposited on the surface. Serna and colleagues assembled purified human complement proteins on liposomes and studied functional pores by cryo-electron microscopy and dye release; they distinguished complete pores from assembly precursors that can insert without spanning the bilayer. A single sketched IgG or a drawn pore-subunit count is not an activation requirement or a measured molecular stoichiometry.","Killing and engulfment experiments commit sampled cell aliquots to the experiment, so budget them separately from fixed sections and untouched material. If complement recruitment increases but measured target viability is unchanged at the stated time, those observations do not demonstrate increased killing. This is a reading rule for the stated observations, not a treatment-effect estimate."],"category":"Immunology"},"route":"/terms/adcc-adcp-cdc/","neighbours":{"term":[{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/"},{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/"},{"id":"isotypes-and-fc-silencing","kind":"term","name":"Antibody isotypes and Fc silencing","route":"/terms/isotypes-and-fc-silencing/"},{"id":"antibody-structure","kind":"term","name":"Antibody structure (Fab, Fc and hinge)","route":"/terms/antibody-structure/"},{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/"},{"id":"macrophage","kind":"term","name":"Macrophage","route":"/terms/macrophage/"},{"id":"nk-cell","kind":"term","name":"NK cell","route":"/terms/nk-cell/"}],"pathway":[{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/"}],"target":[{"id":"fcgr2a","kind":"target","name":"FCGR2A","route":"/targets/fcgr2a/"},{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/"},{"id":"fcgr3a","kind":"target","name":"FCGR3A","route":"/targets/fcgr3a/"}]}}